Clinical trial
Targeting Peroxisome Proliferator-Activated Receptor-Gamma in Peritoneal Dialysis Patients - Will it Reduce Inflammation, Atherosclerosis, Calcification and Improve Survival of Peritoneal Dialysis Patients? (PROOF Trial)
NCT00745225 is registered in ClinicalTrials.gov with The University of Hong Kong as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Targeting Peroxisome Proliferator-Activated Receptor-Gamma in Peritoneal Dialysis Patients - Will it Reduce Inflammation, Atherosclerosis, Calcification and Improve Survival of Peritoneal Dialysis Patients? (PROOF Trial)
- Lead sponsor
- The University of Hong Kong
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- February 28, 2006
- Completion date
- December 31, 2014
- Enrollment
- 160 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
end-stage renal disease